Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
Not yet recruiting · NCT06762223 · Registry updated 2025-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, diabetes mellitus, endocrine system disorder, glucose metabolism disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | Not yet recruiting | Phase 4 | 2025-01-07 | NCT06762223 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu Hengrui Pharmaceutical Co., Ltd. | 29 |
| Xiqiao Zhou | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jiangsu province hospital of traditional chinese medicine | Nanjing | China | 1 |